Inovio Pharmaceuticals (INO) 11.20 $INO
Could Inovio Pharmaceuticals Inc. Be Running Out of Money?
Sean Williams, The Motley Fool - Motley Fool - Thu Oct 23, 7:04AM CDT
Source: Inovio Pharmaceuticals. When it comes to investing your money, the biotech sector is truly like no other industry. While all investors are forward-looking in determining a company's value , sometimes the entire valuation of a biotech stock...
INO: 11.20 (+0.25)
Nasdaq stocks posting largest percentage decreases
AP - Tue Oct 21, 12:44PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
ASPS: 71.74 (+2.63), TKMR: 19.82 (+0.55), RMBS: 10.42 (+0.14), ENTA: 44.97 (+1.14), TKM.TO: 22.32 (+0.55), OMER: 12.18 (+0.42), INO: 11.20 (+0.25), SHOO: 29.78 (-0.22), RCII: 29.52 (-0.08), SCYX: 6.74 (+0.25), AMIC: 10.56 (+0.52), LAKE: 15.26 (+2.13), FBSS: 19.90 (-0.05)
Inovio Pharmaceuticals, MedImmune and the University of Pennsylvania Partner to Combat Influenza and Antibiotic Resistant Bacteria
PR Newswire - Tue Oct 21, 5:00AM CDT
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the Defense Advanced Research Projects Agency (DARPA) has awarded $12.2 million for a collaborative study that will be conducted by scientists from the Perelman School of Medicine at the University of Pennsylvania; Inovio Pharmaceuticals; and MedImmune, the global biologics research and development arm of AstraZeneca. The group will develop DNA-based monoclonal antibodies (mAbs) for infectious disease treatment. DARPA is an agency of the US Department of Defense that creates and supports novel technologies important for national security.
INO: 11.20 (+0.25)
Competitor Analysis: Ebola Virus Vaccines and Therapeutics Report 2014 Featuring Over 30 Insitutions
M2 - Tue Oct 21, 3:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nkwpbp/competitor) has announced the addition of the "Competitor Analysis: Ebola Virus Vaccines and Therapeutics" report to their offering. The present Competitive Intelligence Report about prophylaxis and therapy of Ebola virus infections provides a competitor evaluation in the field of new molecules for prevention or treatment of Ebola virus infections as of October 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently active projects in research and development of therapeutic antibodies, immunoglobulins, RNA, proteins, vaccines and small molecules for prevention and treatment of Ebola virus infections. In addition, the report lists company-specific R&D pipelines of Ebola virus vaccines and therapeutics. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage Key Topics Covered: 1. Ebola Virus Vaccines 2. Ebola Virus Therapeutics 3. Corporate Ebola Virus Vaccines & Therapeutics R&D Pipeline Companies Mentioned - Bavarian Nordic - Biocryst Pharmaceuticals - Chimerix - Defyrus - Fab'entech - Fujifilm Holdings - GlaxoSmithKline (Wellcome Trust; Okairos) - Hemispherx - Immunovaccine - Inovio Pharmaceuticals - Ivanov Institute (of Russian Health Ministry) - Johnson & Johnson (Crucell) - LeafBio - Mapp Biopharmaceuticals - MediVector - Mitsubishi Tanabe Pharma (Medicago) - Nanoviricides - National Institutes of Health (NIH) / National Institute of Allergy and Infectious Diseases (NIAID) - NewLink Genetics (BioProtection Systems) - Novartis - Pentamer Pharmaceuticals - Profectus Biosciences - Public Health Agency of Canada - Sarepta Therapeutics - Tekmira - Thomas Jefferson University - United States Army Medical Research Institute for Infectious Diseases (USAMRIID) - US Department of Defense's Defense Threat Reduction Agency (DTRA) - Vaxart - Walter Reed Army Institute of Research (WRAIR) For more information visit http://www.researchandmarkets.com/research/nkwpbp/competitor
JNJ: 102.63 (+1.41), INO: 11.20 (+0.25), SRPT: 23.04 (+0.75), NLNK: 39.08 (-0.74), GSK: 45.36 (+0.95), NVS: 89.24 (+1.04)
Global Ebola Virus Vaccine Market & Pipeline Insight Report 2014 - Analysis of 26 Clinical Trials & 15 in Preclinical Phase
M2 - Mon Oct 20, 10:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h5mpff/ebola_virus) has announced the addition of the "Ebola Virus Vaccine Market & Pipeline Insight" report to their offering. In terms of treatment, till date, there is not standard treatment method for Ebola hemorrhagic fever. Only supportive therapy is available. Also, there is no licensed vaccine for Ebola virus infection which is of clinical use. The researchers have been trying to better understand this virus and target its ecological reservoirs in order to get a deeper understanding of the cause and nature of the outbreaks of this disease. There are currently many experiments in the laboratories which are focusing on developing an appropriate vaccine for the prevention of this disease, but no success has been met till now. The pharma companies have a significant opportunity in the field of Ebola virus infections in terms of developing drugs, vaccines and introducing measures to control and prevent the spread of the disease. After the success of the clinical candidates, and the market approval of these drugs or vaccines, it is most likely that there could a significant demand for these products from the physicians and patients. Additionally, due to the nature of the disease, these products would be priced at a premium, which would eventually yield high revenues for the companies which would earn a significant return on investment. Ebola Virus Vaccine Market & Pipeline Insight Report Highlight: - Ebola Virus Infection Market Overview - Ebola Vaccine Clinical Trial Insight by Phase, Company & Country - Ebola Vaccine in Clinical Trials: 26 Vaccine - Majority Ebola Vaccine in Preclinical Phase: 15 Vaccines - Ebola Vaccines by Mechanism of Action, Drug Class, Route of administration, Patent Analysis & Licensing Status Key Topics Covered: 1. Ebola Virus Infection Market Overview - Symptoms & Diagnostics - Causes of Ebola Virus Infection - Incidence - Ongoing developments - Future Scenario 2. Ebola Vaccine Clinical Trial Overview 3. Ebola Vaccine Clinical Trial Insight by Phase, Company & Country - Research - Preclinical - Clinical - Phase-I 4. Suspended & Discontinued Ebola Vaccine Clinical Trial Insight by Phase, Company & Country - No Development Reported - Discontinued - Suspended 5. Competitive Landscape - Bavarian Nordic - Crucell - Fab Entech - Inovio Pharmaceuticals - Microbiotix - Mitsubishi Tanabe Pharma - Profectus Biosciences - SIGA Technologies - Tekmira Pharmaceuticals - Vaxart For more information visit http://www.researchandmarkets.com/research/h5...bola_virus
INO: 11.20 (+0.25), TKMR: 19.82 (+0.55)
Healthcare Stocks in Focus on Ebola Fears - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 1:34PM CDT
The WHO has declared the Ebola epidemic a public health emergency of international concern.
AGN: 183.37 (+0.56), INO: 11.20 (+0.25), BCRX: 12.19 (+0.49), SRPT: 23.04 (+0.75), NLNK: 39.08 (-0.74), TKMR: 19.82 (+0.55), GSK: 45.36 (+0.95)
Ebola Viral Infections Therapeutics Pipeline Review, H2 2014 Report - 23 Companies & 30+ Drug Profiles
M2 - Thu Oct 16, 5:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mzj43q/ebola_viral) has announced the addition of the "Ebola Viral Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ebola Viral Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ebola Viral Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Ebola Viral Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Ebola Viral Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Ebola Viral Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Ebola Viral Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Tekmira Pharmaceuticals Corp. - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Toyama Chemical Co., Ltd. - Crucell N.V. - Medicago Inc. - NanoViricides, Inc. - BioCryst Pharmaceuticals, Inc. - Summit Corporation plc - AlphaVax, Inc. - Chimerix, Inc. - Microbiotix, Inc. - Immunovaccine, Inc. - Integrated BioTherapeutics, Inc. - Vaxart, Inc. - Profectus BioSciences, Inc. - Navigen Pharmaceuticals, Inc. - Inhibikase Therapeutics, Inc. - Humabs BioMed SA - Mapp Biopharmaceutical, Inc. - NewLink Genetics Corporation - Epirus Biopharmaceuticals, Inc. Drug Profiles - Recombinant Vector Vaccine for Multivalent Filovirus - TKM-100802 - brincidofovir - favipiravir - Filovirus Vaccine - Drugs for Ebola and Marburg Infections - SMT-15000 - panfilovirus vaccine - BCX-4430 - ET-007 - ZMapp - Polyvalent DNA Vaccine for Ebola and Marburg Filoviruses - ZMAb - MVA-BN-Filoviruses Vaccine - ebola virus vaccine - ebola and marburg vaccine (trivalent) - TKM-100701 - MMCatLMC - ebola and marburg rabies vaccine - Monoclonal Antibodies for Viral Infections - imatinib mesylate - oxocarbazate - thiocarbazate - EMER-IT - Ebola Vaccine - Synthetic Peptides for Ebola Virus - Monoclonal Antibodies for Ebola and Marburg Infections - ARD-5 - 1-E703 For more information visit http://www.researchandmarkets.com/research/mz...bola_viral
INO: 11.20 (+0.25), BCRX: 12.19 (+0.49), CMRX: 32.06 (+1.45), NLNK: 39.08 (-0.74), TKMR: 19.82 (+0.55), NNVC: 3.44 (+0.04), GSK: 45.36 (+0.95)
Ebola Outbreak Puts the Spotlight on 10 Biotech Companies
at The Street - Wed Oct 08, 11:32AM CDT
The Ebola outbreak has put the spotlight on Chimerix as well as other biotech companies with potential vaccines and even those stocks with marginal relation to the virus.
INO: 11.20 (+0.25), BCRX: 12.19 (+0.49), CMRX: 32.06 (+1.45), HEB: 0.30 (unch), SRPT: 23.04 (+0.75), NLNK: 39.08 (-0.74), TKMR: 19.82 (+0.55), LAKE: 15.26 (+2.13), GSK: 45.36 (+0.95)
Inovio Biomedical Rises 1.09% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Oct 06, 5:13PM CDT
Inovio Biomedical (AMEX:INO) traded in a range yesterday that spanned from a low of $10.66 to a high of $11.60. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $11.29 on volume of 3.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
INO: 11.20 (+0.25)
3 Big-Volume Biotech Stocks to Trade for Breakouts
at The Street - Mon Oct 06, 8:31AM CDT
These biotech stocks rising on unusual volume are within range of triggering breakout trades.
AGTC: 18.89 (+0.96), INO: 11.20 (+0.25), PTLA: 27.29 (+0.81)
Technical Updates on Health Care Sector Stocks - AstraZeneca, Novartis, Salix Pharma, Inovio Pharma, and CTI BioPharma
PR Newswire - Mon Oct 06, 8:15AM CDT
Investor-Edge has initiated coverage on the following equities: AstraZeneca PLC (NYSE: AZN), Novartis AG (NYSE: NVS), Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), Inovio Pharmaceuticals Inc. (NASDAQ: INO), and CTI BioPharma Corporation (NASDAQ: CTIC). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Friday, October 03, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,009.69, up 1.24% and the NASDAQ Composite closed at 4,475.62, up 1.03%. The S&P 500 finished the session 1.12% higher at 1,967.90. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 745.09, up 1.97%, with the index advancing 3.29% in the previous three months. Register for your complimentary reports on these five stocks at:
INO: 11.20 (+0.25), AZN: 69.35 (+0.57), SLXP: 135.56 (-2.05), CTIC: 2.37 (+0.08), NVS: 89.24 (+1.04)
What's Next: Investors Place Ebola Pandemic Stock Bets
ACCESSWIRE - Mon Oct 06, 6:59AM CDT
Los Angeles, CA / October 6, 2014 / The recent outbreaks of Ebola in Africa and the first case found in the U.S. have also heightened the FDA's awareness of disease outbreaks and the need for stronger safety measures, but nothing gets investors salivating more that and constant media attention.
INO: 11.20 (+0.25), HEB: 0.30 (unch), TKMR: 19.82 (+0.55)
Critical Alerts For General Electric, Inovio Pharmaceuticals, Mylan, Rite Aid and Delta Airlines Released By InvestorsObserver
PR Newswire - Fri Oct 03, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GE, INO, MYL, RAD and DAL.
INO: 11.20 (+0.25), GE: 25.44 (+0.25), DAL: 37.92 (+0.62), MYL: 50.43 (+0.07), RAD: 4.86 (-0.02)
'Fast Money' Recap: It's Bargain-Hunting Time as the Market Falls
at The Street - Thu Oct 02, 4:00AM CDT
The trading panel discussed world economic weakness and which stocks to buy on lower prices.
F: 14.40 (+0.27), BBRY: 10.31 (+0.42), INVN: 21.42 (+0.45), WYNN: 183.49 (+1.07), JBLU: 10.86 (-0.32), PTEN: 25.81 (+0.82), YHOO: 42.60 (+0.60), ATVI: 19.06 (+0.02), INO: 11.20 (+0.25), EBAY: 50.79 (+0.66), ANGI: 6.81 (+0.14), AGU: 86.38 (+1.25), MPEL: 25.62 (+0.04), COST: 130.59 (+0.05), GOOGL: 553.65 (+10.96), GDX: 20.56 (+0.12), OXY: 91.01 (+1.31), CSCO: 23.57 (+0.31), AMZN: 313.18 (+0.21), SF: 44.74 (+0.75), FB: 80.04 (+1.67), POT: 32.54 (-0.24), PCLN: 1,130.98 (+16.53), NFLX: 383.04 (+8.39), NIB: 40.79 (+0.20), PF: 33.01 (+0.04), IWM: 110.88 (+1.93), YELP: 57.17 (-13.06), BABA: 94.45 (+2.82)
Ahead of the Bell: Ebola treatment makers rise
By The Associated Press - AP - Wed Oct 01, 6:56AM CDT
Shares of several drugmakers developing potential vaccines or treatments for the deadly Ebola virus rose in premarket trading Wednesday, continuing a run that started Tuesday after federal officials confirmed that the first case of the disease has been diagnosed in the United States.
INO: 11.20 (+0.25), TKMR: 19.82 (+0.55), TKM.TO: 22.32 (+0.55)
Shares of companies testing Ebola vaccines rise
AP - Tue Sep 30, 5:58PM CDT
NEW YORK (AP) — Shares of some companies that are studying potential vaccines for Ebola climbed after federal officials announced that the first case of the disease has been diagnosed in the U.S.
INO: 11.20 (+0.25), SRPT: 23.04 (+0.75), TKMR: 19.82 (+0.55), TKM.TO: 22.32 (+0.55)
Inovio Pharmaceuticals Appoints Vice President of Commercial Development
PR Newswire - Tue Sep 30, 6:00AM CDT
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced the appointment of Jennifer Laux as Vice President, Commercial. In this position she will be charged with the development of Inovio's commercialization strategy for its growing portfolio of oncology and infectious disease DNA immunotherapies. As Inovio advances its lead program into phase III, Ms. Laux will direct commercial development for the company's immunotherapies to treat HPV and the pre-cancers and cancers caused by this infection.
INO: 11.20 (+0.25), MRK: 56.63 (+1.12), PG: 83.23 (-1.00)
Inovio/GeneOne Life Science Collaborate for Ebola Vaccine - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 4:00PM CDT
Inovio Pharmaceuticals, Inc. (INO) is collaborating with GeneOne Life Science for the development of a DNA-based Ebola vaccine.
INO: 11.20 (+0.25), JNJ: 102.63 (+1.41), AMGN: 147.25 (+3.61), GSK: 45.36 (+0.95)
Inovio Pharmaceutical
at Investor's Business Daily - Wed Sep 24, 5:30PM CDT
Inovio Pharmaceutical (INO)plans to start human testing of a DNA-based Ebola vaccine after successful studies on guinea pigs and mice. Shares rose 5.3% to 10.29.
INO: 11.20 (+0.25)
Inovio Pharma plans humans trials of Ebola vaccine
AP - Wed Sep 24, 12:17PM CDT
NEW YORK (AP) — Inovio Pharmaceuticals plans to initiate human testing of a DNA-based vaccine for the Ebola virus in the first half of 2015.
INO: 11.20 (+0.25)
Could Inovio Pharmaceuticals Inc. Be Running Out of Money?
Sean Williams, The Motley Fool - Motley Fool - Thu Oct 23, 7:04AM CDT
Source: Inovio Pharmaceuticals. When it comes to investing your money, the biotech sector is truly like no other industry. While all investors are forward-looking in determining a company's value , sometimes the entire valuation of a biotech stock...
INO: 11.20 (+0.25)
Nasdaq stocks posting largest percentage decreases
AP - Tue Oct 21, 12:44PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
ASPS: 71.74 (+2.63), TKMR: 19.82 (+0.55), RMBS: 10.42 (+0.14), ENTA: 44.97 (+1.14), TKM.TO: 22.32 (+0.55), OMER: 12.18 (+0.42), INO: 11.20 (+0.25), SHOO: 29.78 (-0.22), RCII: 29.52 (-0.08), SCYX: 6.74 (+0.25), AMIC: 10.56 (+0.52), LAKE: 15.26 (+2.13), FBSS: 19.90 (-0.05)
Inovio Pharmaceuticals, MedImmune and the University of Pennsylvania Partner to Combat Influenza and Antibiotic Resistant Bacteria
PR Newswire - Tue Oct 21, 5:00AM CDT
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the Defense Advanced Research Projects Agency (DARPA) has awarded $12.2 million for a collaborative study that will be conducted by scientists from the Perelman School of Medicine at the University of Pennsylvania; Inovio Pharmaceuticals; and MedImmune, the global biologics research and development arm of AstraZeneca. The group will develop DNA-based monoclonal antibodies (mAbs) for infectious disease treatment. DARPA is an agency of the US Department of Defense that creates and supports novel technologies important for national security.
INO: 11.20 (+0.25)
Competitor Analysis: Ebola Virus Vaccines and Therapeutics Report 2014 Featuring Over 30 Insitutions
M2 - Tue Oct 21, 3:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nkwpbp/competitor) has announced the addition of the "Competitor Analysis: Ebola Virus Vaccines and Therapeutics" report to their offering. The present Competitive Intelligence Report about prophylaxis and therapy of Ebola virus infections provides a competitor evaluation in the field of new molecules for prevention or treatment of Ebola virus infections as of October 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently active projects in research and development of therapeutic antibodies, immunoglobulins, RNA, proteins, vaccines and small molecules for prevention and treatment of Ebola virus infections. In addition, the report lists company-specific R&D pipelines of Ebola virus vaccines and therapeutics. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage Key Topics Covered: 1. Ebola Virus Vaccines 2. Ebola Virus Therapeutics 3. Corporate Ebola Virus Vaccines & Therapeutics R&D Pipeline Companies Mentioned - Bavarian Nordic - Biocryst Pharmaceuticals - Chimerix - Defyrus - Fab'entech - Fujifilm Holdings - GlaxoSmithKline (Wellcome Trust; Okairos) - Hemispherx - Immunovaccine - Inovio Pharmaceuticals - Ivanov Institute (of Russian Health Ministry) - Johnson & Johnson (Crucell) - LeafBio - Mapp Biopharmaceuticals - MediVector - Mitsubishi Tanabe Pharma (Medicago) - Nanoviricides - National Institutes of Health (NIH) / National Institute of Allergy and Infectious Diseases (NIAID) - NewLink Genetics (BioProtection Systems) - Novartis - Pentamer Pharmaceuticals - Profectus Biosciences - Public Health Agency of Canada - Sarepta Therapeutics - Tekmira - Thomas Jefferson University - United States Army Medical Research Institute for Infectious Diseases (USAMRIID) - US Department of Defense's Defense Threat Reduction Agency (DTRA) - Vaxart - Walter Reed Army Institute of Research (WRAIR) For more information visit http://www.researchandmarkets.com/research/nkwpbp/competitor
JNJ: 102.63 (+1.41), INO: 11.20 (+0.25), SRPT: 23.04 (+0.75), NLNK: 39.08 (-0.74), GSK: 45.36 (+0.95), NVS: 89.24 (+1.04)
Global Ebola Virus Vaccine Market & Pipeline Insight Report 2014 - Analysis of 26 Clinical Trials & 15 in Preclinical Phase
M2 - Mon Oct 20, 10:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h5mpff/ebola_virus) has announced the addition of the "Ebola Virus Vaccine Market & Pipeline Insight" report to their offering. In terms of treatment, till date, there is not standard treatment method for Ebola hemorrhagic fever. Only supportive therapy is available. Also, there is no licensed vaccine for Ebola virus infection which is of clinical use. The researchers have been trying to better understand this virus and target its ecological reservoirs in order to get a deeper understanding of the cause and nature of the outbreaks of this disease. There are currently many experiments in the laboratories which are focusing on developing an appropriate vaccine for the prevention of this disease, but no success has been met till now. The pharma companies have a significant opportunity in the field of Ebola virus infections in terms of developing drugs, vaccines and introducing measures to control and prevent the spread of the disease. After the success of the clinical candidates, and the market approval of these drugs or vaccines, it is most likely that there could a significant demand for these products from the physicians and patients. Additionally, due to the nature of the disease, these products would be priced at a premium, which would eventually yield high revenues for the companies which would earn a significant return on investment. Ebola Virus Vaccine Market & Pipeline Insight Report Highlight: - Ebola Virus Infection Market Overview - Ebola Vaccine Clinical Trial Insight by Phase, Company & Country - Ebola Vaccine in Clinical Trials: 26 Vaccine - Majority Ebola Vaccine in Preclinical Phase: 15 Vaccines - Ebola Vaccines by Mechanism of Action, Drug Class, Route of administration, Patent Analysis & Licensing Status Key Topics Covered: 1. Ebola Virus Infection Market Overview - Symptoms & Diagnostics - Causes of Ebola Virus Infection - Incidence - Ongoing developments - Future Scenario 2. Ebola Vaccine Clinical Trial Overview 3. Ebola Vaccine Clinical Trial Insight by Phase, Company & Country - Research - Preclinical - Clinical - Phase-I 4. Suspended & Discontinued Ebola Vaccine Clinical Trial Insight by Phase, Company & Country - No Development Reported - Discontinued - Suspended 5. Competitive Landscape - Bavarian Nordic - Crucell - Fab Entech - Inovio Pharmaceuticals - Microbiotix - Mitsubishi Tanabe Pharma - Profectus Biosciences - SIGA Technologies - Tekmira Pharmaceuticals - Vaxart For more information visit http://www.researchandmarkets.com/research/h5...bola_virus
INO: 11.20 (+0.25), TKMR: 19.82 (+0.55)
Healthcare Stocks in Focus on Ebola Fears - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 1:34PM CDT
The WHO has declared the Ebola epidemic a public health emergency of international concern.
AGN: 183.37 (+0.56), INO: 11.20 (+0.25), BCRX: 12.19 (+0.49), SRPT: 23.04 (+0.75), NLNK: 39.08 (-0.74), TKMR: 19.82 (+0.55), GSK: 45.36 (+0.95)
Ebola Viral Infections Therapeutics Pipeline Review, H2 2014 Report - 23 Companies & 30+ Drug Profiles
M2 - Thu Oct 16, 5:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mzj43q/ebola_viral) has announced the addition of the "Ebola Viral Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ebola Viral Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ebola Viral Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Ebola Viral Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Ebola Viral Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Ebola Viral Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Ebola Viral Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Tekmira Pharmaceuticals Corp. - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Toyama Chemical Co., Ltd. - Crucell N.V. - Medicago Inc. - NanoViricides, Inc. - BioCryst Pharmaceuticals, Inc. - Summit Corporation plc - AlphaVax, Inc. - Chimerix, Inc. - Microbiotix, Inc. - Immunovaccine, Inc. - Integrated BioTherapeutics, Inc. - Vaxart, Inc. - Profectus BioSciences, Inc. - Navigen Pharmaceuticals, Inc. - Inhibikase Therapeutics, Inc. - Humabs BioMed SA - Mapp Biopharmaceutical, Inc. - NewLink Genetics Corporation - Epirus Biopharmaceuticals, Inc. Drug Profiles - Recombinant Vector Vaccine for Multivalent Filovirus - TKM-100802 - brincidofovir - favipiravir - Filovirus Vaccine - Drugs for Ebola and Marburg Infections - SMT-15000 - panfilovirus vaccine - BCX-4430 - ET-007 - ZMapp - Polyvalent DNA Vaccine for Ebola and Marburg Filoviruses - ZMAb - MVA-BN-Filoviruses Vaccine - ebola virus vaccine - ebola and marburg vaccine (trivalent) - TKM-100701 - MMCatLMC - ebola and marburg rabies vaccine - Monoclonal Antibodies for Viral Infections - imatinib mesylate - oxocarbazate - thiocarbazate - EMER-IT - Ebola Vaccine - Synthetic Peptides for Ebola Virus - Monoclonal Antibodies for Ebola and Marburg Infections - ARD-5 - 1-E703 For more information visit http://www.researchandmarkets.com/research/mz...bola_viral
INO: 11.20 (+0.25), BCRX: 12.19 (+0.49), CMRX: 32.06 (+1.45), NLNK: 39.08 (-0.74), TKMR: 19.82 (+0.55), NNVC: 3.44 (+0.04), GSK: 45.36 (+0.95)
Ebola Outbreak Puts the Spotlight on 10 Biotech Companies
at The Street - Wed Oct 08, 11:32AM CDT
The Ebola outbreak has put the spotlight on Chimerix as well as other biotech companies with potential vaccines and even those stocks with marginal relation to the virus.
INO: 11.20 (+0.25), BCRX: 12.19 (+0.49), CMRX: 32.06 (+1.45), HEB: 0.30 (unch), SRPT: 23.04 (+0.75), NLNK: 39.08 (-0.74), TKMR: 19.82 (+0.55), LAKE: 15.26 (+2.13), GSK: 45.36 (+0.95)
Inovio Biomedical Rises 1.09% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Oct 06, 5:13PM CDT
Inovio Biomedical (AMEX:INO) traded in a range yesterday that spanned from a low of $10.66 to a high of $11.60. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $11.29 on volume of 3.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
INO: 11.20 (+0.25)
3 Big-Volume Biotech Stocks to Trade for Breakouts
at The Street - Mon Oct 06, 8:31AM CDT
These biotech stocks rising on unusual volume are within range of triggering breakout trades.
AGTC: 18.89 (+0.96), INO: 11.20 (+0.25), PTLA: 27.29 (+0.81)
Technical Updates on Health Care Sector Stocks - AstraZeneca, Novartis, Salix Pharma, Inovio Pharma, and CTI BioPharma
PR Newswire - Mon Oct 06, 8:15AM CDT
Investor-Edge has initiated coverage on the following equities: AstraZeneca PLC (NYSE: AZN), Novartis AG (NYSE: NVS), Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), Inovio Pharmaceuticals Inc. (NASDAQ: INO), and CTI BioPharma Corporation (NASDAQ: CTIC). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Friday, October 03, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,009.69, up 1.24% and the NASDAQ Composite closed at 4,475.62, up 1.03%. The S&P 500 finished the session 1.12% higher at 1,967.90. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 745.09, up 1.97%, with the index advancing 3.29% in the previous three months. Register for your complimentary reports on these five stocks at:
INO: 11.20 (+0.25), AZN: 69.35 (+0.57), SLXP: 135.56 (-2.05), CTIC: 2.37 (+0.08), NVS: 89.24 (+1.04)
What's Next: Investors Place Ebola Pandemic Stock Bets
ACCESSWIRE - Mon Oct 06, 6:59AM CDT
Los Angeles, CA / October 6, 2014 / The recent outbreaks of Ebola in Africa and the first case found in the U.S. have also heightened the FDA's awareness of disease outbreaks and the need for stronger safety measures, but nothing gets investors salivating more that and constant media attention.
INO: 11.20 (+0.25), HEB: 0.30 (unch), TKMR: 19.82 (+0.55)
Critical Alerts For General Electric, Inovio Pharmaceuticals, Mylan, Rite Aid and Delta Airlines Released By InvestorsObserver
PR Newswire - Fri Oct 03, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GE, INO, MYL, RAD and DAL.
INO: 11.20 (+0.25), GE: 25.44 (+0.25), DAL: 37.92 (+0.62), MYL: 50.43 (+0.07), RAD: 4.86 (-0.02)
'Fast Money' Recap: It's Bargain-Hunting Time as the Market Falls
at The Street - Thu Oct 02, 4:00AM CDT
The trading panel discussed world economic weakness and which stocks to buy on lower prices.
F: 14.40 (+0.27), BBRY: 10.31 (+0.42), INVN: 21.42 (+0.45), WYNN: 183.49 (+1.07), JBLU: 10.86 (-0.32), PTEN: 25.81 (+0.82), YHOO: 42.60 (+0.60), ATVI: 19.06 (+0.02), INO: 11.20 (+0.25), EBAY: 50.79 (+0.66), ANGI: 6.81 (+0.14), AGU: 86.38 (+1.25), MPEL: 25.62 (+0.04), COST: 130.59 (+0.05), GOOGL: 553.65 (+10.96), GDX: 20.56 (+0.12), OXY: 91.01 (+1.31), CSCO: 23.57 (+0.31), AMZN: 313.18 (+0.21), SF: 44.74 (+0.75), FB: 80.04 (+1.67), POT: 32.54 (-0.24), PCLN: 1,130.98 (+16.53), NFLX: 383.04 (+8.39), NIB: 40.79 (+0.20), PF: 33.01 (+0.04), IWM: 110.88 (+1.93), YELP: 57.17 (-13.06), BABA: 94.45 (+2.82)
Ahead of the Bell: Ebola treatment makers rise
By The Associated Press - AP - Wed Oct 01, 6:56AM CDT
Shares of several drugmakers developing potential vaccines or treatments for the deadly Ebola virus rose in premarket trading Wednesday, continuing a run that started Tuesday after federal officials confirmed that the first case of the disease has been diagnosed in the United States.
INO: 11.20 (+0.25), TKMR: 19.82 (+0.55), TKM.TO: 22.32 (+0.55)
Shares of companies testing Ebola vaccines rise
AP - Tue Sep 30, 5:58PM CDT
NEW YORK (AP) — Shares of some companies that are studying potential vaccines for Ebola climbed after federal officials announced that the first case of the disease has been diagnosed in the U.S.
INO: 11.20 (+0.25), SRPT: 23.04 (+0.75), TKMR: 19.82 (+0.55), TKM.TO: 22.32 (+0.55)
Inovio Pharmaceuticals Appoints Vice President of Commercial Development
PR Newswire - Tue Sep 30, 6:00AM CDT
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced the appointment of Jennifer Laux as Vice President, Commercial. In this position she will be charged with the development of Inovio's commercialization strategy for its growing portfolio of oncology and infectious disease DNA immunotherapies. As Inovio advances its lead program into phase III, Ms. Laux will direct commercial development for the company's immunotherapies to treat HPV and the pre-cancers and cancers caused by this infection.
INO: 11.20 (+0.25), MRK: 56.63 (+1.12), PG: 83.23 (-1.00)
Inovio/GeneOne Life Science Collaborate for Ebola Vaccine - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 4:00PM CDT
Inovio Pharmaceuticals, Inc. (INO) is collaborating with GeneOne Life Science for the development of a DNA-based Ebola vaccine.
INO: 11.20 (+0.25), JNJ: 102.63 (+1.41), AMGN: 147.25 (+3.61), GSK: 45.36 (+0.95)
Inovio Pharmaceutical
at Investor's Business Daily - Wed Sep 24, 5:30PM CDT
Inovio Pharmaceutical (INO)plans to start human testing of a DNA-based Ebola vaccine after successful studies on guinea pigs and mice. Shares rose 5.3% to 10.29.
INO: 11.20 (+0.25)
Inovio Pharma plans humans trials of Ebola vaccine
AP - Wed Sep 24, 12:17PM CDT
NEW YORK (AP) — Inovio Pharmaceuticals plans to initiate human testing of a DNA-based vaccine for the Ebola virus in the first half of 2015.
INO: 11.20 (+0.25)
